These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 307833)

  • 1. Vancomycin effect on thrombin-induced platelet aggregation: evidence against a common platelet membrane receptor for thrombin and ristocetin.
    Weinger RS; Moake JL
    Thromb Res; 1978 May; 12(5):911-15. PubMed ID: 307833
    [No Abstract]   [Full Text] [Related]  

  • 2. Vancomycin as well as ristocetin facilitates von Willebrand factor binding to platelets.
    Suzuki K; Nishioka J; Hashimoto S
    Thromb Res; 1980 Jul 1-15; 19(1-2):287-92. PubMed ID: 6969463
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of vancomycin on ristocetin and bovine PAF-induced agglutination of human platelets.
    Baugh RF; Jacoby C; Brown JE; Hougie C
    Thromb Res; 1978 Mar; 12(3):511-21. PubMed ID: 306689
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of ristocetin-induced platelet agglutination by vancomycin.
    Moake JL; Cimo PL; Peterson DM; Roper P; Natelson EA
    Blood; 1977 Sep; 50(3):397-406. PubMed ID: 301760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization of von Willebrand factor and thrombin-interactive domains on human platelet glycoprotein Ib.
    Katagiri Y; Hayashi Y; Yamamoto K; Tanoue K; Kosaki G; Yamazaki H
    Thromb Haemost; 1990 Feb; 63(1):122-6. PubMed ID: 2339348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease.
    Jenkins CS; Phillips DR; Clemetson KJ; Meyer D; Larrieu MJ; Lüscher EF
    J Clin Invest; 1976 Jan; 57(1):112-24. PubMed ID: 1081991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.
    Coller BS; Gralnick HR
    J Clin Invest; 1977 Aug; 60(2):302-12. PubMed ID: 17620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-binding of the von Willebrand factor.
    Green D; Muller HP
    Thromb Haemost; 1978 Jun; 39(3):689-94. PubMed ID: 309191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies against platelet membrane glycoproteins. III. Effect on thrombin-and bovine Von Willebrand factor-induced aggregation.
    Jenkins CS; Clemetson KJ; Ali-Briggs EF
    Br J Haematol; 1983 Mar; 53(3):491-501. PubMed ID: 6600621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody to glycoprotein Ib inhibits both thrombin- and ristocetin-induced platelet aggregations.
    Yamamoto N; Kitagawa H; Tanoue K; Yamazaki H
    Thromb Res; 1985 Sep; 39(6):751-9. PubMed ID: 2417361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and platelet von Willebrand factor defects in uremia.
    Gralnick HR; McKeown LP; Williams SB; Shafer BC; Pierce L
    Am J Med; 1988 Dec; 85(6):806-10. PubMed ID: 3264111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A monoclonal antibody directed against a granule membrane glycoprotein (GMP-140/PADGEM, P-selectin, CD62P) inhibits ristocetin-induced platelet aggregation.
    Boukerche H; Ruchaud-Sparagano MH; Rouen C; Brochier J; Kaplan C; McGregor JL
    Br J Haematol; 1996 Feb; 92(2):442-51. PubMed ID: 8603015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membrane fluidity and platelet aggregation: dibucaine permits ristocetin-induced platelet aggregation with low-molecular-weight von Willebrand multimers.
    Gjønnaess E; Solum NO; Brosstad F
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):395-405. PubMed ID: 1420815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of ristocetin and von Willebrand factor.
    Jenkins CS; Meyer D; Larrieu MJ
    Thromb Haemost; 1976 Jun; 35(3):752-3. PubMed ID: 1086517
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of an antiglycoprotein Ib monoclonal antibody that specifically inhibits platelet-thrombin interaction.
    Mazurov AV; Vinogradov DV; Vlasik TN; Repin VS; Booth WJ; Berndt MC
    Thromb Res; 1991 Jun; 62(6):673-84. PubMed ID: 1718052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin and thrombin receptor agonist peptide induce tyrosine phosphorylation and tyrosine kinases in the platelet cytoskeleton. Translocation of pp60c-src and integrin alpha IIb beta 3 (glycoprotein IIb/IIIa) is not required for aggregation, but is dependent on formation of large aggregate structures.
    Pumiglia KM; Feinstein MB
    Biochem J; 1993 Aug; 294 ( Pt 1)(Pt 1):253-60. PubMed ID: 7689831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet factor 4 does not promote von Willebrand factor binding to human platelets.
    Levine SP; Moake JL
    Thromb Res; 1984 Nov; 36(3):233-43. PubMed ID: 6440307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Von Willebrand factor has more than one binding site for platelets.
    Nokes TJ; Mahmoud NA; Savidge GF; Goodall AH; Meyer D; Edgington TS; Hardisty RM
    Thromb Res; 1984 Jun; 34(5):361-6. PubMed ID: 6610952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ristocetin- and thrombin-induced platelet aggregation at physiological shear rates: differential roles for GPIb and GPIIb-IIIa receptor.
    Kasirer-Friede A; Frojmovic MM
    Thromb Haemost; 1998 Sep; 80(3):428-36. PubMed ID: 9759623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet receptors for human Factor VIII/von Willebrand protein: functional correlation of receptor occupancy and ristocetin-induced platelet aggregation.
    Kao KJ; Pizzo SV; McKee PA
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5317-20. PubMed ID: 315561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.